Cells that survived one year could slow the darkness
For the first time, transplanted neural progenitor cells have survived a full year inside the retinas of patients losing their sight to retinitis pigmentosa — a disease that has, until now, offered most of those it claims no treatment at all. Presented at a major stem cell research conference in 2026, this small but carefully watched trial suggests that cells placed beneath the retina can take root, persist, and do so without serious harm. What makes the finding philosophically as well as medically significant is that the approach does not ask which gene is broken — it works regardless, offering a rare mutation-agnostic path through a condition defined by its genetic fragmentation. The question that remains, as it always does at the frontier of medicine, is whether surviving is enough, or whether these cells can also protect.
- Retinitis pigmentosa fragments into thousands of genetic variants, meaning most patients fall outside the narrow reach of existing gene therapies and face progressive blindness with no recourse.
- Thirteen patients received subretinal injections of fetal-derived neural progenitor cells, and after twelve months those cells were confirmed alive and in place — a milestone no previous trial had reached.
- Visual acuity held stable across the cohort, and while three patients developed epiretinal membranes and one a retinal fluid pocket, no serious adverse events emerged — a favorable safety signal in a high-stakes field.
- The therapy's mutation-independence is its strategic edge: where gene therapies must be rebuilt for each genetic variant, this cell-based approach functions the same way regardless of which gene is broken.
- The next phase of the trial will determine whether engrafted cells can actually slow vision deterioration, while a parallel iPSC-based version is being developed to scale the therapy beyond the ethical and logistical limits of fetal tissue.
Thirteen people with retinitis pigmentosa received injections of human neural progenitor cells placed directly beneath their retinas. A year later, those cells remained alive and in place — the first demonstration that fetal-derived neural progenitors can achieve long-term survival in patients with this progressive inherited eye disease. The finding was presented at the International Society for Stem Cell Research conference in 2026.
Retinitis pigmentosa is not a single condition but a family of diseases driven by thousands of different genetic mutations, all converging on the same outcome: slow, irreversible vision loss. Because the genetic landscape is so fragmented, most patients have no treatment available to them. Gene therapies, which must be tailored to specific mutations, can only reach a fraction of those affected.
The trial used a product called CNS10-NPC — neural progenitor cells derived from fetal brain tissue — injected into the subretinal space at either 300,000 or 1,000,000 cells per patient. Over twelve months, visual acuity remained stable, and optical coherence tomography confirmed the cells had engrafted. Three patients developed epiretinal membranes and one a persistent fluid pocket beneath the retina — manageable complications in a field where the alternative is blindness.
The approach's key advantage is its indifference to the underlying genetic cause. In animal models, transplanted cells reduced retinal inflammation and released growth factors that protected photoreceptors from dying. Whether that protection holds in humans over years remains the central unanswered question. Clive Svendsen of Cedars-Sinai, who sponsored the study, described one-year engraftment as a critical prerequisite — without it, no cell-based therapy can offer sustained benefit.
The research team is continuing to follow the thirteen patients to determine whether surviving cells can slow vision loss. In parallel, they are developing an iPSC-based version of the therapy using reprogrammed adult cells rather than fetal tissue — a more scalable and ethically uncomplicated alternative still in preclinical testing. If the approach proves durable, it could eventually reach the many thousands of patients for whom no treatment currently exists.
Thirteen people with retinitis pigmentosa sat for injections that placed human neural progenitor cells directly beneath their retinas. A year later, those cells were still there, still alive, still functioning without causing serious harm. This is the first time anyone has shown that fetal-derived neural progenitor cells can survive long-term in patients with this progressive inherited eye disease, and the finding, presented at the International Society for Stem Cell Research conference in 2026, opens a door that has been closed for decades.
Retinitis pigmentosa is not one disease but a family of them—thousands of different genetic mutations can trigger the same outcome: slow, relentless vision loss. Because the genetic landscape is so fragmented, developing treatments has meant chasing individual mutations one at a time, a strategy that leaves most patients without options. The disease progresses at different speeds in different people, but it progresses. There is currently no cure for the vast majority of those affected.
The clinical trial was small and tightly controlled. Researchers injected either 300,000 or 1,000,000 cells of a product called CNS10-NPC—neural progenitor cells grown from fetal brain tissue—into the subretinal space of each participant. They then watched. Over twelve months, visual acuity remained stable. Optical coherence tomography imaging, a detailed scanning technique, confirmed that the transplanted cells had taken root and persisted in the space where they were placed. Three patients developed epiretinal membranes, a type of scar tissue on the retina's surface. One developed a persistent fluid pocket beneath the retina. These were manageable complications in a field where the alternative is blindness.
What makes this approach different from gene therapy is its indifference to the underlying genetic cause. Gene therapies must be tailored to specific mutations—a treatment for one variant of retinitis pigmentosa does nothing for another. Neural progenitor cell transplantation, by contrast, works the same way regardless of which gene is broken. The cells appear to function through a mechanism that does not depend on correcting any particular genetic error. In animal models, the transplanted cells reduced inflammation in the retina and released growth factors that protected the light-sensitive photoreceptor cells from dying. Whether that same protection translates to humans over years and decades remains the crucial unanswered question.
Clive Svendsen, who directs the regenerative medicine institute at Cedars-Sinai and sponsored the study, called the one-year survival milestone critical. Long-term engraftment—the ability of transplanted cells to take hold and persist—is a prerequisite for any cell-based therapy to work. Without it, the treatment is merely a temporary intervention. With it, there is at least the possibility of sustained benefit. The clinical team, led by researcher Liao, is continuing to follow the thirteen patients to see whether the surviving cells can actually slow the vision loss that defines retinitis pigmentosa. That is the real test. Stability over one year is encouraging. Stability over five years, or ten, would be transformative.
The researchers are also developing an alternative version of the therapy using induced pluripotent stem cells—adult cells reprogrammed to an embryonic state and then coaxed into becoming neural progenitors. This approach would be more scalable, capable of treating far more patients than a therapy dependent on fetal tissue sources. It would also sidestep the ethical concerns that have long shadowed fetal cell research. The iPSC version is still in preclinical testing, but its parallel development suggests that if this approach works, it could eventually reach many thousands of people who currently have no treatment at all. For now, the field is watching the thirteen patients in this trial, waiting to see whether cells that survived one year can do what no therapy has yet done: hold back the darkness.
Citações Notáveis
Long-term engraftment is a critical milestone for the development of stem cell-based therapies for retinal disease and provides an important foundation for future studies.— Clive Svendsen, Cedars-Sinai Board of Governors Regenerative Medicine Institute
Our goal is to help patients maintain their vision for as long as possible. The next critical question is whether these surviving cells can slow the continued deterioration that occurs in retinitis pigmentosa.— Liao, clinical lead on the project
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that these cells survived a full year? Couldn't they have just been sitting there inert?
Because cell survival is the foundation. If the cells died after three months, the whole approach fails. But if they're still there after a year, still integrated into the tissue, then there's a real possibility they're doing something—releasing those growth factors, reducing inflammation, protecting the photoreceptors that are still functioning.
And the vision didn't get worse. But it also didn't get better, right?
Right. The disease progresses slowly, so they didn't expect dramatic improvement in year one. The real question is whether these cells can slow that progression over time. That's what they're watching for now.
Why is the mutation-agnostic angle so important? Couldn't you just develop more gene therapies?
You could, but you'd need a different therapy for each mutation. There are thousands of them. A cell therapy that works regardless of which gene is broken reaches a much larger population with a single treatment approach.
What about those complications—the scar tissue, the fluid pocket?
They happened in a small number of patients and were manageable. In the context of a disease that causes blindness, they're acceptable trade-offs. But they're worth monitoring as the therapy scales up.
The iPSC version sounds like it solves the ethical problem. Why not just skip the fetal cells and go straight there?
Because you need to prove the concept works first. The fetal cell version is the proof of principle. Once you know the approach is sound, then you can optimize it with iPSCs, which are easier to produce and ethically cleaner. You're building the foundation before you scale the building.